<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39343986</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1750-2659</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Influenza and other respiratory viruses</Title><ISOAbbreviation>Influenza Other Respir Viruses</ISOAbbreviation></Journal><ArticleTitle>BNT162b2 Versus mRNA-1273 Vaccines: Comparative Analysis of Long-Term Protection Against SARS-CoV-2 Infection and Severe COVID-19 in Qatar.</ArticleTitle><Pagination><StartPage>e13357</StartPage><MedlinePgn>e13357</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e13357</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/irv.13357</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study provides a head-to-head comparison of the protection provided by the BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2 infection and against severe COVID-19, covering primary series and third dose/booster vaccinations over up to 3 years of follow-up, both before and after the emergence of the omicron variant.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Two national, matched, retrospective cohort studies were conducted on Qatar's vaccinated population from December 16, 2020, to February 18, 2024. Subgroup analyses by pre-vaccination SARS-CoV-2 infection history, as well as sensitivity analyses, were also conducted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The adjusted hazard ratio (AHR) comparing infection incidence in those vaccinated with BNT162b2 versus mRNA-1273 was 1.03 (95% CI: 1.02-1.05) after the primary series and 1.11 (95% CI: 1.09-1.13) after the third (booster) dose. The corresponding AHRs for any severe, critical, or fatal COVID-19 were 1.31 (95% CI: 0.81-2.11) and 1.00 (95% CI: 0.20-4.94), respectively. Subgroup analyses by prior infection status hinted at a dose-dependent immune imprinting effect, where a combination of two types of immunity, pre-omicron and omicron, offered greater protection against infection than one type alone, with this effect being amplified by the higher antigen dose of mRNA-1273 compared to BNT162b2. Sensitivity analyses confirmed the study findings.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">BNT162b2 provided slightly less protection against infection than mRNA-1273 following both primary series and booster vaccinations while offering comparable protection against severe COVID-19 outcomes. The findings suggested that the vaccine antigen dose in interaction with infection history may determine the extent of immune protection against infection.</AbstractText><CopyrightInformation>© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chemaitelly</LastName><ForeName>Hiam</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-8756-6968</Identifier><AffiliationInfo><Affiliation>Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayoub</LastName><ForeName>Houssein H</ForeName><Initials>HH</Initials><Identifier Source="ORCID">0000-0003-2512-6657</Identifier><AffiliationInfo><Affiliation>Mathematics Program, Department of Mathematics and Statistics, College of Arts and Sciences, Qatar University, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coyle</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pathology, Sidra Medicine, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasan</LastName><ForeName>Mohammad R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0002-4658-7949</Identifier><AffiliationInfo><Affiliation>Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yassine</LastName><ForeName>Hadi M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research Center, QU Health, Qatar University, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al Thani</LastName><ForeName>Asmaa A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research Center, QU Health, Qatar University, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Kanaani</LastName><ForeName>Zaina</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Kuwari</LastName><ForeName>Einas</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeremijenko</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaleeckal</LastName><ForeName>Anvar Hassan</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latif</LastName><ForeName>Ali Nizar</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaik</LastName><ForeName>Riyazuddin Mohammad</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdul-Rahim</LastName><ForeName>Hanan F</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasrallah</LastName><ForeName>Gheyath K</ForeName><Initials>GK</Initials><Identifier Source="ORCID">0000-0001-9252-1038</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Research Center, QU Health, Qatar University, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Kuwari</LastName><ForeName>Mohamed Ghaith</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Primary Health Care Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butt</LastName><ForeName>Adeel A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Weill Cornell Medicine, Cornell University, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Romaihi</LastName><ForeName>Hamad Eid</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Ministry of Public Health, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Thani</LastName><ForeName>Mohamed H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Ministry of Public Health, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Khal</LastName><ForeName>Abdullatif</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hamad Medical Corporation, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertollini</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ministry of Public Health, Doha, Qatar.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abu-Raddad</LastName><ForeName>Laith J</ForeName><Initials>LJ</Initials><Identifier Source="ORCID">0000-0003-0790-0506</Identifier><AffiliationInfo><Affiliation>Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>College of Health and Life Sciences, Hamad bin Khalifa University, Doha, Qatar.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Weill Cornell Medicine-Qatar</Agency><Country /></Grant><Grant><Agency>Ministry of Public Health</Agency><Country /></Grant><Grant><Agency>Hamad Medical Corporation</Agency><Country /></Grant><Grant><Agency>Sidra Medicine</Agency><Country /></Grant><Grant><Agency>Qatar Genome Programme</Agency><Country /></Grant><Grant><Agency>Qatar University</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Influenza Other Respir Viruses</MedlineTA><NlmUniqueID>101304007</NlmUniqueID><ISSNLinking>1750-2640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EPK39PL4R4</RegistryNumber><NameOfSubstance UI="D000090983">2019-nCoV Vaccine mRNA-1273</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011780" MajorTopicYN="N" Type="Geographic">Qatar</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="Y">BNT162 Vaccine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090983" MajorTopicYN="Y">2019-nCoV Vaccine mRNA-1273</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">cohort study</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">immune imprinting</Keyword><Keyword MajorTopicYN="N">immunity</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList><CoiStatement>Adeel A. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. The other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>30</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>23</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39343986</ArticleId><ArticleId IdType="pmc">PMC11439586</ArticleId><ArticleId IdType="doi">10.1111/irv.13357</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polack F. P., Thomas S. J., Kitchin N., et al., “Safety and Efficacy of the BNT162b2 mRNA Covid‐19 Vaccine,” New England Journal of Medicine 383, no. 27 (2020): 2603–2615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L. R., El Sahly H. M., Essink B., et al., “Efficacy and Safety of the mRNA‐1273 SARS‐CoV‐2 Vaccine,” New England Journal of Medicine 384, no. 5 (2021): 403–416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>
International Vaccine Access Center
, “VIEW‐hub: Covid‐19 Data, Vaccine Studies, Effectiveness Studies,” (2024), accessed March 25, 2024, https://view‐hub.org/covid‐19/effectiveness‐studies/.</Citation></Reference><Reference><Citation>Abu‐Raddad L. J., Chemaitelly H., Ayoub H. H., et al., “Effect of mRNA Vaccine Boosters Against SARS‐CoV‐2 Omicron Infection in Qatar,” New England Journal of Medicine 386, no. 19 (2022): 1804–1816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8929389</ArticleId><ArticleId IdType="pubmed">35263534</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu‐Raddad L. J., Chemaitelly H., Butt A. A., and National Study Group for COVID‐19 Vaccination , “Effectiveness of the BNT162b2 Covid‐19 Vaccine Against the B.1.1.7 and B.1.351 Variants,” New England Journal of Medicine 385, no. 2 (2021): 187–189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8117967</ArticleId><ArticleId IdType="pubmed">33951357</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Yassine H. M., Benslimane F. M., et al., “mRNA‐1273 COVID‐19 Vaccine Effectiveness Against the B.1.1.7 and B.1.351 Variants and Severe COVID‐19 Disease in Qatar,” Nature Medicine 27, no. 9 (2021): 1614–1621.</Citation><ArticleIdList><ArticleId IdType="pubmed">34244681</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Tang P., Hasan M. R., et al., “Waning of BNT162b2 Vaccine Protection Against SARS‐CoV‐2 Infection in Qatar,” New England Journal of Medicine 385, no. 24 (2021): e83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522799</ArticleId><ArticleId IdType="pubmed">34614327</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu‐Raddad L. J., Chemaitelly H., Bertollini R., and National Study Group for COVID‐19 Vaccination , “Waning mRNA‐1273 Vaccine Effectiveness Against SARS‐CoV‐2 Infection in Qatar,” New England Journal of Medicine 386, no. 11 (2022): 1091–1093.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8809505</ArticleId><ArticleId IdType="pubmed">35081294</ArticleId></ArticleIdList></Reference><Reference><Citation>Feikin D. R., Higdon M. M., Abu‐Raddad L. J., et al., “Duration of Effectiveness of Vaccines Against SARS‐CoV‐2 Infection and COVID‐19 Disease: Results of a Systematic Review and Meta‐Regression,” Lancet 399, no. 10328 (2022): 924–944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H. and Abu‐Raddad L. J., “Waning Effectiveness of COVID‐19 Vaccines,” Lancet 399, no. 10327 (2022): 771–773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8871492</ArticleId><ArticleId IdType="pubmed">35219385</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Ayoub H. H., AlMukdad S., et al., “Duration of mRNA Vaccine Protection Against SARS‐CoV‐2 Omicron BA.1 and BA.2 Subvariants in Qatar,” Nature Communications 13, no. 1 (2022): 3082.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9163167</ArticleId><ArticleId IdType="pubmed">35654888</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H. N., Chemaitelly H., Ayoub H. H., et al., “Effects of Previous Infection, Vaccination, and Hybrid Immunity Against Symptomatic Alpha, Beta, and Delta SARS‐CoV‐2 Infections: An Observational Study,” eBioMedicine 95 (2023): 104734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10404859</ArticleId><ArticleId IdType="pubmed">37515986</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H. N., Chemaitelly H., Ayoub H. H., et al., “Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections,” New England Journal of Medicine 387, no. 1 (2022): 21–34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258753</ArticleId><ArticleId IdType="pubmed">35704396</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H. N., Chemaitelly H., Ayoub H. H., et al., “Protective Effect of Previous SARS‐CoV‐2 Infection Against Omicron BA.4 and BA.5 Subvariants,” New England Journal of Medicine 387, no. 17 (2022): 1620–1622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9559315</ArticleId><ArticleId IdType="pubmed">36198139</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Coyle P., Kacem M. A. B., et al., “Protection of Natural Infection Against Reinfection With SARS‐CoV‐2 JN.1 Variant,” Journal of Travel Medicine 31 (2024): taae053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11149714</ArticleId><ArticleId IdType="pubmed">38591115</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Tang P., Coyle P., et al., “Protection Against Reinfection With the Omicron BA.2.75 Subvariant,” New England Journal of Medicine 388, no. 7 (2023): 665–667.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9878583</ArticleId><ArticleId IdType="pubmed">36652342</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu‐Raddad L. J., Chemaitelly H., Bertollini R., and National Study Group for COVID‐19 Vaccination , “Effectiveness of mRNA‐1273 and BNT162b2 Vaccines in Qatar,” New England Journal of Medicine 386, no. 8 (2022): 799–800.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8796790</ArticleId><ArticleId IdType="pubmed">35045222</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury D. S., Cromer D., Reynaldi A., et al., “Neutralizing Antibody Levels Are Highly Predictive of Immune Protection From Symptomatic SARS‐CoV‐2 Infection,” Nature Medicine 27, no. 7 (2021): 1205–1211.</Citation><ArticleIdList><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds C. J., Pade C., Gibbons J. M., et al., “Immune Boosting by B.1.1.529 (Omicron) Depends on Previous SARS‐CoV‐2 Exposure,” Science 377 (2022): eabq1841.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9210451</ArticleId><ArticleId IdType="pubmed">35699621</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Ayoub H. H., Tang P., et al., “Immune Imprinting and Protection Against Repeat Reinfection With SARS‐CoV‐2,” New England Journal of Medicine 387, no. 18 (2022): 1716–1718.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9634858</ArticleId><ArticleId IdType="pubmed">36223534</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Ayoub H. H., Tang P., et al., “History of Primary‐Series and Booster Vaccination and Protection Against Omicron Reinfection,” Science Advances 9, no. 40 (2023): eadh0761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10550237</ArticleId><ArticleId IdType="pubmed">37792951</ArticleId></ArticleIdList></Reference><Reference><Citation>Roltgen K., Nielsen S. C. A., Silva O., et al., “Immune Imprinting, Breadth of Variant Recognition, and Germinal Center Response in Human SARS‐CoV‐2 Infection and Vaccination,” Cell 185, no. 6 (2022): 1025–1040.e14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786601</ArticleId><ArticleId IdType="pubmed">35148837</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Jian F., Wang J., et al., “Imprinted SARS‐CoV‐2 Humoral Immunity Induces Convergent Omicron RBD Evolution,” Nature 614, no. 7948 (2023): 521–529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9931576</ArticleId><ArticleId IdType="pubmed">36535326</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Ayoub H. H., Tang P., et al., “Long‐Term COVID‐19 Booster Effectiveness by Infection History and Clinical Vulnerability and Immune Imprinting: A Retrospective Population‐Based Cohort Study,” Lancet Infectious Diseases 23, no. 7 (2023): 816–827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10079373</ArticleId><ArticleId IdType="pubmed">36913963</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha N. K., Burke P. C., Nowacki A. S., Simon J. F., Hagen A., and Gordon S. M., “Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine,” Open Forum Infectious Diseases 10, no. 6 (2023): ofad209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10234376</ArticleId><ArticleId IdType="pubmed">37274183</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Ayoub H. H., AlMukdad S., et al., “Bivalent mRNA‐1273.214 Vaccine Effectiveness Against SARS‐CoV‐2 Omicron XBB* Infections,” Journal of Travel Medicine 30, no. 5 (2023): taad106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10481416</ArticleId><ArticleId IdType="pubmed">37555656</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu‐Raddad L. J., Chemaitelly H., Ayoub H. H., et al., “Characterizing the Qatar Advanced‐Phase SARS‐CoV‐2 Epidemic,” Scientific Reports 11, no. 1 (2021): 6233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7973743</ArticleId><ArticleId IdType="pubmed">33737535</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Faust J. S., Krumholz H. M., et al., “Short‐ and Longer‐Term all‐Cause Mortality Among SARS‐CoV‐2‐ Infected Individuals and the Pull‐Forward Phenomenon in Qatar: A National Cohort Study,” International Journal of Infectious Diseases 136 (2023): 81–90.</Citation><ArticleIdList><ArticleId IdType="pubmed">37717648</ArticleId></ArticleIdList></Reference><Reference><Citation>AlNuaimi A. A., Chemaitelly H., Semaan S., et al., “All‐Cause and COVID‐19 Mortality in Qatar During the COVID‐19 Pandemic,” BMJ Global Health 8, no. 5 (2023): e012291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10163334</ArticleId><ArticleId IdType="pubmed">37142299</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernan M. A. and Robins J. M., “Using big Data to Emulate a Target Trial When a Randomized Trial Is Not Available,” American Journal of Epidemiology 183, no. 8 (2016): 758–764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832051</ArticleId><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. V., Schneeweiss S., Initiative R.‐D., et al., “Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses: Results of 32 Clinical Trials,” Journal of the American Medical Association 329, no. 16 (2023): 1376–1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10130954</ArticleId><ArticleId IdType="pubmed">37097356</ArticleId></ArticleIdList></Reference><Reference><Citation>
World Health Organization (WHO)
, “Living Guidance for Clinical Management of COVID‐19,” (2023), accessed February 27, 2023, https://www.who.int/publications/i/item/WHO‐2019‐nCoV‐clinical‐2021‐2.</Citation></Reference><Reference><Citation>
World Health Organization (WHO)
, “International Guidelines for Certification and Classification (Coding) of COVID‐19 as Cause of Death,” (2023), accessed February 27, 2023, https://www.who.int/publications/m/item/international‐guidelines‐for‐certification‐and‐classification‐(coding)‐of‐covid‐19‐as‐cause‐of‐death.</Citation></Reference><Reference><Citation>Pilz S., Theiler‐Schwetz V., Trummer C., Krause R., and Ioannidis J. P. A., “SARS‐CoV‐2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity,” Environmental Research 209 (2022): 112911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8824301</ArticleId><ArticleId IdType="pubmed">35149106</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima N., Shrestha N. K., and Klausner J. D., “A Systematic Review of the Protective Effect of Prior SARS‐CoV‐2 Infection on Repeat Infection,” Evaluation &amp; the Health Professions 44, no. 4 (2021): 327–332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8564250</ArticleId><ArticleId IdType="pubmed">34592838</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Ayoub H. H., Tang P., et al., “Addressing Bias in the Definition of SARS‐CoV‐2 Reinfection: Implications for Underestimation,” Frontiers in Medicine 11 (2024): 1363045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10961414</ArticleId><ArticleId IdType="pubmed">38529118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoub H. H., Chemaitelly H., Seedat S., et al., “Mathematical Modeling of the SARS‐CoV‐2 Epidemic in Qatar and Its Impact on the National Response to COVID‐19,” Journal of Global Health 11 (2021): 05005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7897910</ArticleId><ArticleId IdType="pubmed">33643638</ArticleId></ArticleIdList></Reference><Reference><Citation>Coyle P. V., Chemaitelly H., Ben Hadj Kacem M. A., et al., “SARS‐CoV‐2 Seroprevalence in the Urban Population of Qatar: An Analysis of Antibody Testing on a Sample of 112,941 Individuals,” iScience 24, no. 6 (2021): 102646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8142077</ArticleId><ArticleId IdType="pubmed">34056566</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeremijenko A., Chemaitelly H., Ayoub H. H., et al., “Herd Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar,” Emerging Infectious Diseases 27, no. 5 (2021): 1343–1352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8084480</ArticleId><ArticleId IdType="pubmed">33900174</ArticleId></ArticleIdList></Reference><Reference><Citation>Al‐Thani M. H., Farag E., Bertollini R., et al., “SARS‐CoV‐2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar,” Open Forum Infectious Diseases 8, no. 8 (2021): ofab221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8135898</ArticleId><ArticleId IdType="pubmed">34458388</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Ayoub H. H., Coyle P., et al., “Protection of Omicron Sub‐lineage Infection Against Reinfection With Another Omicron Sub‐lineage,” Nat Commun. 13, no. 1 (2022): 4675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9362989</ArticleId><ArticleId IdType="pubmed">35945213</ArticleId></ArticleIdList></Reference><Reference><Citation>Barda N., Dagan N., Cohen C., et al., “Effectiveness of a Third Dose of the BNT162b2 mRNA COVID‐19 Vaccine for Preventing Severe Outcomes in Israel: An Observational Study,” Lancet 398, no. 10316 (2021): 2093–2100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8555967</ArticleId><ArticleId IdType="pubmed">34756184</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin P. C., “Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research,” Communications in Statistics ‐ Simulation and Computation 38, no. 6 (2009): 1228–1234.</Citation></Reference><Reference><Citation>Sjolander A. and Greenland S., “Ignoring the Matching Variables in Cohort Studies ‐ When Is It Valid and Why?” Statistics in Medicine 32, no. 27 (2013): 4696–4708.</Citation><ArticleIdList><ArticleId IdType="pubmed">23761197</ArticleId></ArticleIdList></Reference><Reference><Citation>Stensrud M. J. and Hernan M. A., “Why Test for Proportional Hazards?” Journal of the American Medical Association 323, no. 14 (2020): 1401–1402.</Citation><ArticleIdList><ArticleId IdType="pubmed">32167523</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans J. P., Zeng C., Carlin C., et al., “Neutralizing Antibody Responses Elicited by SARS‐CoV‐2 mRNA Vaccination Wane Over Time and Are Boosted by Breakthrough Infection,” Science Translational Medicine 14, no. 637 (2022): eabn8057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8939766</ArticleId><ArticleId IdType="pubmed">35166573</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin E. G., Lustig Y., Cohen C., et al., “Waning Immune Humoral Response to BNT162b2 Covid‐19 Vaccine Over 6 Months,” New England Journal of Medicine 385, no. 24 (2021): e84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Ayoub H. H., Coyle P., et al., “BNT162b2 Antigen Dose and SARS‐CoV‐2 Omicron Infection in Adolescents,” Lancet Infectious Diseases 23, no. 3 (2023): 276–277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9891733</ArticleId><ArticleId IdType="pubmed">36738760</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty A. L., Peyser N. D., Butcher X. E., et al., “Analysis of COVID‐19 Vaccine Type and Adverse Effects Following Vaccination,” JAMA Network Open 4, no. 12 (2021): e2140364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8696570</ArticleId><ArticleId IdType="pubmed">34935921</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Ayoub H. H., Faust J. S., et al., “Turning Point in COVID‐19 Severity and Fatality During the Pandemic: A National Cohort Study in Qatar,” BMJ Public Health 1, no. 1 (2023): e000479.</Citation></Reference><Reference><Citation>Abu‐Raddad L. J., Chemaitelly H., Yassine H. M., et al., “Pfizer‐BioNTech mRNA BNT162b2 Covid‐19 Vaccine Protection Against Variants of Concern After one Versus Two Doses,” Journal of Travel Medicine 28, no. 7 (2021): taab083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8194836</ArticleId><ArticleId IdType="pubmed">34050372</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>